Aptinyx
Aptinyx Inc. is a now-delisted, clinical-stage biopharmaceutical company that developed neuroscience therapeutics, backed by dedicated life-sciences venture capital and NIH grant funding.
- Company typePrivate
- Founded2015
- HeadquartersEvanston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Aptinyx does
Aptinyx Inc. is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Evanston, Illinois. The company was previously listed on the NASDAQ under the ticker APTX and is now flagged as delisted. Aptinyx operated with a headcount of 51–100 employees and was led by an experienced biopharma management team, including Norbert Riedel and Andy Kidd in President/CEO roles, Joseph Moskal as Chief Scientific Officer (a co-founder with Northwestern University roots), Ashish Khanna as Chief Financial Officer and Chief Business Officer, and Wilbur Gantz as Chairman of the Board. The company's investor base included dedicated life-sciences venture firms such as Bain Capital Life Sciences, New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Adams Street Partners, and Rock Springs Capital, alongside a non-dilutive $5.6M award from the National Institutes of Health in November 2022.
Across six disclosed funding rounds between 2016 and 2022, Aptinyx raised approximately $273.9 million in cumulative capital, with rounds led by New Leaf Venture Partners (2016, $65M), Bain Capital Life Sciences (2017, $70M), Savitr Capital (2020, $48.3M), and K2 HealthVentures (2021, $50M). Financials for 2018–2021 reflect sustained, material operating losses consistent with a clinical-stage R&D organization — gross profit and net income figures shown in the input are clearly malformed (trillion-dollar magnitudes) and should be disregarded, but the directional signal is unambiguous: pre-commercial, cash-consuming biotech with no product revenue. The delisting from NASDAQ, the absence of any venture round after 2021, and the pivot to a small NIH grant in late 2022 collectively indicate a contracting or wind-down posture rather than active commercial expansion. No products, approved therapies, partnership economics, or customer relationships are disclosed in the input.
Aptinyx firmographics
Firmographics- Name
- Aptinyx
- Legal name
- Amplinyx Inc.
- Website
- https://aptinyx.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 51–100 employees
- Short description
- Aptinyx Inc. is a now-delisted, clinical-stage biopharmaceutical company that developed neuroscience therapeutics, backed by dedicated life-sciences venture capital and NIH grant funding.
- Ownership category
- akta.pro rank
Aptinyx industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals (CNS Therapeutics)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Aptinyx is headquartered
LocationHeadquarters
- HQ city
- Evanston
- HQ country
- United States
- HQ region
- North America
Markets served
Aptinyx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- SaaS Subscription - Team Plans: Team-based subscription pricing model targeting teams of 3-100 users with shared projects, analytics, conversation oversight, and centralized billing features
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Team Plan - 3 to 100 users |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Aptinyx product offering
Product offeringCore offering
Aptinyx is a clinical-stage biopharmaceutical company developing proprietary small-molecule therapeutics that modulate NMDA receptors and related CNS targets. The company's portfolio historically focused on indications in neuroscience, including neuropathic pain, PTSD, and cognitive impairment. Operations centered on advancing compounds through preclinical and clinical development rather than commercial product sales.
Product overview
Amplinyx Inc. offers NexPhrase as a unified AI communication coaching platform. The core product is NexPhrase, which provides real-time conversation coaching with real-time, context-aware guidance. The platform expanded with the Self-Learning AI feature (November 2025) that enables adaptive coaching based on user interactions, and the Team Plan (November 2025) which adds enterprise collaboration features for teams of 3-100 users including shared projects, analytics, and centralized billing.
Differentiator
Problem solved
Functional benefit
Brands
- NexPhrase: AI communication coaching platform offering real-time, context-aware guidance during high-stakes conversations with deployment options for web and desktop systems
- NexPhrase Team Plan
- NexPhrase Self-Learning AI
Products and services
- NYX-2925
Companies that use Aptinyx
Customer profileSegments1 record
Ideal customer profiles1 record
Aptinyx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
Aptinyx partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Aptinyx competitors and assessment
Company assessmentDirect peers
- Sage Therapeutics: Sage Therapeutics is a clinical-stage and commercial CNS-focused biopharmaceutical company developing therapies for depression, epilepsy, and other CNS disorders. Highly comparable to Aptinyx as a small-cap CNS specialty pharma with NMDA/GABA-related mechanism focus and similar size profile.
- Marinus Pharmaceuticals: Marinus Pharmaceuticals developed Ztalmy (ganaxolone) for CDKL5 deficiency disorder and other CNS epilepsies. Highly comparable to Aptinyx as a small-cap CNS specialty pharma with similar clinical-stage profile and orphan CNS indication focus.
- Axsome Therapeutics: Axsome Therapeutics is a CNS-focused biopharmaceutical company developing therapies for migraines, depression, and other neurological conditions. Comparable to Aptinyx as a small-cap CNS specialty pharma targeting similar indications with novel small-molecule approaches.
- Intra-Cellular Therapies: Intra-Cellular Therapies developed and commercialized Caplyta for CNS indications before being acquired by J&J. Closely comparable to Aptinyx in CNS specialty pharma model with similar size and clinical-development profile prior to acquisition.
- Karuna Therapeutics: Karuna Therapeutics developed xanomeline-trospium (Cobenfy) for schizophrenia before being acquired by Bristol Myers Squibb for $14B. Comparable to Aptinyx in CNS specialty pharma focus with novel small-molecule CNS mechanism targeting high-value indications.
Broad incumbents
- Acadia Pharmaceuticals: Acadia Pharmaceuticals is a commercial-stage biopharma focused on CNS disorders including Parkinson's disease psychosis and Rett syndrome. Comparable to Aptinyx in CNS specialty pharma focus, though Acadia is more mature with multiple approved products.
Emerging players
- Neumora Therapeutics: Neumora Therapeutics is a clinical-stage CNS biopharma focused on neuropsychiatric and neurodegenerative diseases. Comparable to Aptinyx as an emerging CNS specialty pharma with multiple clinical-stage CNS candidates and significant private capital backing.
- Tonix Pharmaceuticals: Tonix Pharmaceuticals is a clinical-stage CNS specialty pharma developing therapies for PTSD, migraine, and other CNS conditions. Notably comparable to Aptinyx given overlapping PTSD indication focus (similar to Aptinyx's NYX-783 program).
- Praxis Precision Medicines: Praxis Precision Medicines is a clinical-stage CNS biopharma developing therapies for epilepsy and other CNS disorders. Comparable to Aptinyx as a small-cap CNS specialty pharma with similar clinical-stage profile and orphan CNS indication focus.
- BioXcel Therapeutics: BioXcel Therapeutics is a clinical-stage biopharmaceutical company using AI for CNS and immuno-oncology drug development. Comparable to Aptinyx in CNS specialty pharma focus, with emerging pipeline in agitation and other CNS indications.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Aptinyx social profiles
Digital presenceAptinyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aptinyx leadership team
Management profileNumber of profiles
Profiles5 records
Aptinyx funding detail
Funding detailFunding overview
Funding rounds6 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aptinyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aptinyx
What does Aptinyx do?
Aptinyx is a clinical-stage biopharmaceutical company developing proprietary small-molecule therapeutics that modulate NMDA receptors and related CNS targets. The company's portfolio historically focused on indications in neuroscience, including neuropathic pain, PTSD, and cognitive impairment. Operations centered on advancing compounds through preclinical and clinical development rather than commercial product sales.
When was Aptinyx founded?
Aptinyx was founded in 2015. It employs 51 to 100 people.
Where is Aptinyx based?
Aptinyx is headquartered in Evanston, United States, in the North America region.
How does Aptinyx make money?
One revenue line is on record: saaS Subscription - Team Plans.
Who are Aptinyx's main competitors?
Direct peers on record are Sage Therapeutics, Marinus Pharmaceuticals, Axsome Therapeutics, Intra-Cellular Therapies and Karuna Therapeutics. Acadia Pharmaceuticals is listed as a broad incumbent. Emerging players are Neumora Therapeutics, Tonix Pharmaceuticals, Praxis Precision Medicines and BioXcel Therapeutics.
Does Aptinyx have an API?
No public API is recorded for Aptinyx.
What industry is Aptinyx in?
Aptinyx's product category is Clinical-stage Biopharmaceuticals (CNS Therapeutics). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.